ImmunoPrecise Antibodies Ltd (IPA) concluded trading on Wednesday at a closing price of $0.64, with 327.07 million shares of worth about $209.32 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -24.18% during that period and on January 22, 2025 the price saw a gain of about 30.73%. Currently the company’s common shares owned by public are about 30.29M shares, out of which, 20.47M shares are available for trading.
Stock saw a price change of 40.11% in past 5 days and over the past one month there was a price change of 48.85%. Year-to-date (YTD), IPA shares are showing a performance of 56.55% which decreased to -56.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.32 but also hit the highest price of $2.60 during that period. The average intraday trading volume for ImmunoPrecise Antibodies Ltd shares is 625.50K. The stock is currently trading 32.88% above its 20-day simple moving average (SMA20), while that difference is up 46.82% for SMA50 and it goes to -17.74% lower than SMA200.
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) currently have 30.29M outstanding shares and institutions hold larger chunk of about 7.71% of that.
The stock has a current market capitalization of $20.01M and its 3Y-monthly beta is at 0.21. It has posted earnings per share of -$0.75 in the same period. It has Quick Ratio of 0.85 while making debt-to-equity ratio of 0.50. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IPA, volatility over the week remained 23.46% while standing at 15.17% over the month.
Analysts are in expectations that ImmunoPrecise Antibodies Ltd (IPA) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 63.12% while it is estimated to increase by 53.71% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 02, 2022 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by The Benchmark Company stated ImmunoPrecise Antibodies Ltd (IPA) stock as a Buy in their note to investors on October 25, 2021, suggesting a price target of $12 for the stock.
